

Carmela Cursaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5097766/publications.pdf>

Version: 2024-02-01

47
papers

1,997
citations

361413
20
h-index

243625
44
g-index

47
all docs

47
docs citations

47
times ranked

2599
citing authors

#	ARTICLE	IF	CITATIONS
1	Virological Treatment Monitoring for Chronic Hepatitis B. <i>Viruses</i> , 2022, 14, 1376.	3.3	1
2	Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 568-575.	2.0	15
3	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. <i>Annals of Hepatology</i> , 2018, 17, 64-75.	1.5	46
4	Vitamin E for the treatment of E antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. <i>Liver International</i> , 2017, 37, 54-61.	3.9	5
5	Tenofovir-induced Fanconi syndrome in a patient with chronic hepatitis B mono-infection. <i>Annals of Hepatology</i> , 2016, 15, 273-6.	1.5	8
6	Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. <i>Annals of Hepatology</i> , 2014, 13, 196-203.	1.5	1
7	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 225-233.	3.7	202
8	Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2013, 56, 291-295.	3.1	18
9	Virus-Specific Immune Response in HBsAg-Negative Chronic Hepatitis B: Relationship with Clinical Profile and HBsAg Serum Levels. <i>PLoS ONE</i> , 2013, 8, e65327.	2.5	36
10	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1658-1665.	2.9	201
11	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 2011, 5, 82-89.	0.3	1
12	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011, 105, 982-989.	2.3	10
13	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. <i>World Journal of Gastroenterology</i> , 2009, 15, 5946.	3.3	3
14	Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620080287-bcr0620080287.	0.5	1
15	Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. <i>Liver International</i> , 2008, 28, 407-411.	3.9	9
16	Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. <i>Liver Transplantation</i> , 2008, 14, 478-485.	2.4	6
17	Evaluation of the effects of human leukocyte IFN- γ on the immune response to the HBV vaccine in healthy unvaccinated individuals. <i>Vaccine</i> , 2008, 26, 1038-1049.	3.8	19
18	A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2007, 42, 362-367.	5.1	7

#	ARTICLE	IF	CITATIONS
19	Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?. American Journal of Gastroenterology, 2006, 101, 524-532.	0.4	391
20	Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Digestive and Liver Disease, 2006, 38, 27-32.	0.9	44
21	Acquired intestinal lymphangiectasia successfully treated with a low-fat and medium-chain triacylglycerol-enriched diet in a patient with liver transplantation. European Journal of Gastroenterology and Hepatology, 2006, 18, 561-564.	1.6	10
22	Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir. Journal of Clinical Microbiology, 2006, 44, 1094-1097.	3.9	56
23	Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. Journal of Viral Hepatitis, 2005, 12, 525-530.	2.0	62
24	Transcatheter Arterial Chemoembolization Therapy for Patients With Hepatocellular Carcinoma: A Case-Controlled Study. Clinical Gastroenterology and Hepatology, 2005, 3, 918-925.	4.4	32
25	Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. Journal of Hepatology, 2005, 43, 937-943.	3.7	207
26	High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. Journal of Viral Hepatitis, 2004, 11, 439-442.	2.0	60
27	Thymosin-alpha 1 plus interferon-alpha for naïve patients with chronic hepatitis C: results of a randomized controlled pilot trial. Journal of Viral Hepatitis, 2004, 11, 69-73.	2.0	20
28	In vitro effect of indomethacin and interferon- α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. Cytokine, 2004, 26, 95-101.	3.2	12
29	Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial. Journal of Viral Hepatitis, 2003, 10, 306-309.	2.0	13
30	Prophylaxis and treatment of hepatitis B virus infection after liver transplantation. Transplantation Proceedings, 2003, 35, 1022-1024.	0.6	0
31	Posttransplantation Lymphoproliferative Disorders. Archives of Internal Medicine, 2003, 163, 1997.	3.8	79
32	Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study. Digestive and Liver Disease, 2001, 33, 693-697.	0.9	17
33	In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2001, 8, 194-201.	2.0	44
34	Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Research, 2001, 49, 75-81.	4.1	71
35	Interferon- α plus ribavirin in chronic hepatitis C resistant to previous interferon- α course: results of a randomized multicenter trial. Journal of Hepatology, 1999, 30, 788-793.	3.7	45
36	Thymalfasin. BioDrugs, 1998, 9, 477-486.	4.6	11

#	ARTICLE	IF	CITATIONS
37	Interferon and hepatocellular carcinoma. Lancet, The, 1996, 347, 194-195.	13.7	15
38	A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver, 1996, 16, 207-210.	0.1	31
39	Hemodynamic and renal effects of ascites apheresis, concentration and reinfusion in advanced cirrhosis. Journal of Hepatology, 1995, 22, 10-16.	3.7	23
40	Indomethacin enhances serum 25-OH-vitamin D ₃ production in patients with hepatitis B and C virus chronic active hepatitis. Journal of Hepatology, 1994, 21, 984-988.	3.7	24
41	Interferon- α increases prostaglandin E ₂ production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?. Journal of Hepatology, 1993, 19, 228-231.	3.7	26
42	The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. Hepatology, 1992, 16, 341-346.	7.3	87
43	Interferon- α therapy combined with nonsteroid antiinflammatory drugs for treatment of chronic viral hepatitis?. Hepatology, 1992, 16, 505-505.	7.3	6
44	Role of prostaglandin e ₂ on defective interferon- γ production during type b acute viral hepatitis. Research in Clinic and Laboratory, 1991, 21, 111-117.	0.3	5
45	Clinical significance of antibodies to polymerized human albumin detected by enzyme-linked immunosorbent assay. Research in Clinic and Laboratory, 1988, 18, 291-300.	0.3	2
46	Unaltered dopaminergic modulation of aldosterone secretion in cirrhosis. Clinical Science, 1988, 74, 137-143.	4.3	15
47	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. Italian Journal of Medicine, 0, , 82-89.	0.3	0